The table below shows MoonLake Immunotherapeutics's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$66.29M
-$38.14M
-$14.95M
-$9.02M
-$14.19M
-$107.80K
Capital expenditure
$0.00
$35.00K
$212.00K
$0.00
$16.01K
-
Investing cash flow
$98.00K
$56.25M
-$28.80M
$19.65M
-$16.01K
-
Dividends paid
-
-
-
-
MLTX operating cash flow (10-K history)
MoonLake Immunotherapeutics reported operating cash flow of -$196.01M for fiscal year 2025. That is down 68.1% from -$116.59M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$611.07K (FY 2021) to -$196.01M. Figures come from the company's audited annual reports as filed with the SEC.